ReviewViruses2012
Human metapneumovirus antagonism of innate immune responses.
Review in Viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Resurgence of human metapneumovirus: an overview of past and current trends.Archives of microbiology · 2026Review
- hMPV co-infections: Distinct immunopathogenic mechanisms and clinical implications of viral and bacterial pathogenesis.Folia microbiologica · 2025Review
- Human metapneumovirus: understanding the molecular mechanisms and pathology of infection.Journal of virology · 2025Review
- Immunoinformatic design of chimeric multiepitope vaccine for the prevention of human metapneumovirus (hMPV).BMC infectious diseases · 2025Article
- Review
- Review
- Interplay between endogenous hormones and immune systems in human metapneumovirus pathogenesis and management.Frontiers in pharmacology · 2025Review
- ETV2 transcriptionally activates Rig1 gene expression and promotes reprogramming of the endothelial lineage.Scientific reports · 2024Article
- Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice.NPJ vaccines · 2024Article
- Effects of G and SH Truncation on the Replication, Virulence, and Immunogenicity of Avian Metapneumovirus.Vaccines · 2024Article
- Clinical significance of human metapneumovirus detection in critically ill adults with lower respiratory tract infections.Annals of intensive care · 2023Article
- New Insights into the Host-Pathogen Interaction ofMicroorganisms · 2021Article
- Review
- The Host Response to Viral Infections Reveals Common and Virus-Specific Signatures in the Peripheral Blood.Frontiers in immunology · 2021Article
- Prophylactic and therapeutic approaches for human metapneumovirus.Virusdisease · 2018Review
- Interleukin-6 and Interferon-α SignalingFrontiers in immunology · 2018Article
- Premature infants have impaired airway antiviral IFNγ responses to human metapneumovirus compared to respiratory syncytial virus.Pediatric research · 2015Article
- New Approaches for Immunization and Therapy against Human Metapneumovirus.Clinical and vaccine immunology : CVI · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human metapneumovirus (hMPV) is a recently identified RNA virus belonging to the Paramyxoviridae family, which includes several major human and animal pathogens. Epidemiological studies indicate that hMPV is a significant human respiratory pathogen with worldwide distribution. It is associated with respiratory illnesses in children, adults, and immunocompromised patients, ranging from upper respiratory tract infections to severe bronchiolitis and pneumonia. Interferon (IFN) represents a major line of defense against virus infection, and in response, viruses have evolved countermeasures to inhibit IFN production as well as IFN signaling. Although the strategies of IFN evasion are similar, the specific mechanisms by which paramyxoviruses inhibit IFN responses are quite diverse. In this review, we will present an overview of the strategies that hMPV uses to subvert cellular signaling in airway epithelial cells, the major target of infection, as well as in primary immune cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.